Literature DB >> 1701346

Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells.

D Siegel1, N W Gibson, P C Preusch, D Ross.   

Abstract

The role of DT-diaphorase in bioreductive activation of mitomycin C was examined using HT-29 and BE human carcinoma cells which have high and low levels of DT-diaphorase activity, respectively. HT-29 cells were more sensitive to mitomycin C-induced cytotoxicity than the DT-diaphorase-deficient BE cell line. Mitomycin C induced DNA interstrand cross-linking in HT-29 cells but not in BE cells. Both mitomycin C-induced cytotoxicity and induction of DNA interstrand cross-links could be inhibited by pretreatment of HT-29 cells with dicoumarol. Metabolism of mitomycin C by HT-29 cell cytosol was pH dependent and increased as the pH was lowered to 5.8, the lowest pH tested. Metabolism of mitomycin C by HT-29 cytosol was inhibited by prior boiling of cytosol or by the inclusion of dicoumarol. Little metabolism was detected in BE cytosols. When purified rat hepatic DT-diaphorase was used, metabolism of mitomycin C increased as the pH was decreased and could be detected at pH 5.8, 6.4, 7.0, 7.4, but not at 7.8. Metabolism of mitomycin C was NADH dependent and inhibited by dicoumarol or by prior boiling of enzyme. An approximate 1:1 stoichiometry between NADH and mitomycin C removal was demonstrated and no oxygen consumption could be detected. Metabolism of mitomycin C by purified HT-29 DT-diaphorase was also dicoumarol inhibitable and pH dependent. The major metabolite formed during metabolism of mitomycin C by HT-29 cytosol, purified HT-29, and rat hepatic DT-diaphorase was characterized as 2,7-diaminomitosene. These data suggest that two-electron reduction of mitomycin C by DT-diaphorase may be an important determinant of mitomycin C-induced genotoxicity and cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1701346

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

Review 1.  Enzymology of bioreductive drug activation.

Authors:  D Ross; H D Beall; D Siegel; R D Traver; D L Gustafson
Journal:  Br J Cancer Suppl       Date:  1996-07

Review 2.  Mitomycinoid alkaloids: mechanism of action, biosynthesis, total syntheses, and synthetic approaches.

Authors:  Phillip D Bass; Daniel A Gubler; Ted C Judd; Robert M Williams
Journal:  Chem Rev       Date:  2013-05-08       Impact factor: 60.622

Review 3.  Cellular pharmacology of quinone bioreductive alkylating agents.

Authors:  S Rockwell; A C Sartorelli; M Tomasz; K A Kennedy
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

4.  Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9.

Authors:  P M Loadman; M C Bibby; R M Phillips
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

Review 5.  Pharmacotherapy options for locally advanced and advanced cervical cancer.

Authors:  Alfonso Dueñas-González; Lucely Cetina; Jaime Coronel; Déborah Martínez-Baños
Journal:  Drugs       Date:  2010-03-05       Impact factor: 9.546

6.  The human papilloma virus 16E6 gene sensitizes human mammary epithelial cells to apoptosis induced by DNA damage.

Authors:  C Xu; W Meikrantz; R Schlegel; R Sager
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

7.  Development and initial characterization of a mitomycin C-resistant colon cancer cell line variant.

Authors:  R R Perry; B R Greaves; Y Kang
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours.

Authors:  D Hussein; S V Holt; K E Brookes; T Klymenko; J K Adamski; A Hogg; E J Estlin; T Ward; C Dive; G W J Makin
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

9.  Isolation and characterization of a mitomycin C-resistant variant of human colon carcinoma HT-29 cells.

Authors:  J H Lee; M Naito; M Nakajima; T Tsuruo
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  The role of NAD(P)H:quinone oxidoreductase in mitomycin C- and porfiromycin-resistant HCT 116 human colon-cancer cells.

Authors:  S S Pan; S A Akman; G L Forrest; C Hipsher; R Johnson
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.